C ongenital diarrheal disorders are a heterogeneous group of rare inherited enteropathies with a typical onset early in life. Most are monogenic disorders, and the congenital diarrheal disorders can be divided into four groups based on the pathogenic mechanism. These groups include defects in digestion and absorption of nutrients and electrolytes, enterocyte structure, intestinal immune-related homeostasis, and enteroendocrine cell differentiation. Defects in digestion and absorption constitute the largest group of etiologies. (1) Included in this group are loss of function mutations in SLC10A2/ASBT, which cause primary bile acid malabsorption (a distinct subgroup of type 2 bile acid diarrhea). (2, 3) Bile acids are synthesized from cholesterol in the liver and are secreted into the small intestine, where they facilitate absorption of fats, fat-soluble vitamins, and cholesterol. After reaching the terminal ileum, bile acids are absorbed from the intestinal lumen, returned to the liver via the portal venous circulation, and resecreted into bile. Apical sodium-dependent bile acid transporter (ASBT) is the major apical brush border membrane transporter responsible for ileal enterocyte uptake of bile acids from the intestinal lumen. (4) However, in addition to SLC10A2/ASBT, inherited defects in other genes important for the bile acid enterohepatic circulation have been identified that affect hepatic or intestinal function. The list of transporter genes that impact the hepatic secretion of biliary constituents or the enterohepatic cycling of bile acids and the associated diseases or characteristics include: ATP8B1/FIC1 (progressive familial intrahepatic cholestasis type 1; PFIC1), ABCB11/BSEP (PFIC2), ABCB4/MDR3 (PFIC3), SLCO1B1/OATP1B1 and SLCO1B3/ OATP1B3 (Rotor syndrome), and SLC10A1/NTCP (conjugated hypercholanemia). (5) Notably absent from the subgroup of essential bile acid transport proteins with inherited defects associated with disease is the SLC51A-SLC51B (organic solute transporter alphabeta [OSTa-OSTb]) heterodimer, a major basolateral membrane bile acid exporter. (4, 6) OSTa-OSTb functions as a complex consisting of a 340-amino acid polytopic membrane protein (OSTa; gene symbol SLC51A) and a 128-amino acid predicted type Ib membrane protein (OSTb; gene symbol SLC51B). Although the two genes are encoded on separate chromosomes-positions 3q29 and 15q22 for the human SLC51A and SLC51B, respectively-their expression in humans generally parallels one another, with the highest levels in the small intestine, liver, and kidney. (6) Expression of both subunits is absolutely required for trafficking of the OSTa and OSTb proteins from the ER to the plasma membrane and for bile acid transport activity. (6, 7) Deletion of Slc51a in mice leads to loss of expression for Osta and its partner protein Ostb, and these mice exhibit impaired intestinal bile acid absorption. (8, 9) Osta -/-mice also exhibit reduced levels of hepatic bile acid synthesis as a result of altered FXR/FGF15 signaling in the gut-liver axis. (10) No inherited defects in human SLC51A or SLC51B have been reported and the role of defective OSTa-OSTb heterodimers in the pathogenesis of human liver or gastrointestinal diseases is unclear. Here we provide the first report of OSTb (SLC51B) deficiency, identified in a family with two affected brothers who presented with diarrhea, fat-soluble vitamin deficiencies, and elevated liver serum chemistries. As a result of exome sequencing, these patients were identified with an OSTb (SLC51B) deficiency due to a frameshift mutation (p.F27fs) that truncates the OSTb protein and markedly impairs synthesis of the OSTa-OSTb complex and bile acid transport activity. 
Materials and Methods

MATERIALS
BILE ACID MEASUREMENTS
Bile acids in the plasma and urine were measured using high-performance liquid chromatography electrospray tandem mass spectrometry as described. (11) WHOLE EXOME ANALYSIS Exonic sequences were enriched in the DNA samples from the proband (patient 1) using a SureSelect Human All Exon 50 Mb Kit (Agilent Technologies, Santa Clara, CA). Sequences were determined using HiSeq2000 (Illumina, San Diego, CA) and 100 bp were read paired-end. Read alignments and variant calling were performed with DNAnexus software (Palo Alto, CA) using the default parameters with human genome assembly hg19 (GRCh37) as a reference.
ANALYSIS OF PROTEIN EXPRESSION AND ACTIVITY
COS-1 cells were maintained in monolayer at 378C in an atmosphere of 5% CO 2 and grown in media consisting of Dulbecco's modified Eagle's medium containing 4500 mg/L D-glucose, 10% (vol/vol) fetal calf serum, 100 units/ml penicillin and 100 lg/ml streptomycin. On day 0, 100 mm plates were seeded with 1.5 3 10 6 COS cells. On day 1, each plate of cells was transfected using Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific) and the indicated plasmid. On day 2, the transfected cells were trypsinized, pooled, and replated at 3 3 10 5 cells per well in 24-well plates. On day 4, the cells were incubated for 30 minutes at 378C in a modified Hank's balanced salt solution containing 137 mM potassium in the presence of the indicated concentration of [ 3 H]taurocholate. The cells were then washed and harvested to determine cell-associated radioactivity and protein. The uptake is expressed as pmol of taurocholate transported per mg or protein. (7) For immunoblotting analysis of transfected cell extracts, cell monolayers were washed with ice-cold phosphate-buffered saline and scraped in 1 mL icecold phosphate-buffered saline containing protease inhibitors, pelleted, and stored at 2808C. Cell extracts were prepared by lysing the cell pellets in buffer B (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 1 mM CaCl 2 , 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 lg/mL pepstatin, 10 lg/mL aprotonin, 10 lg/mL leupeptin, and 10 mM ethylene diamine tetraacetic acid) by repeated aspiration through a 25-guage needle. The samples were centrifuged at 10,000g for 2 minutes at 48C, and aliquots of cell supernatants were stored at -708C. Samples were diluted into Laemmli sample buffer plus 500 mM iodoacetamide to alkylate any free thiols, heated at 378C for 30 minutes, and subjected to SDS-PAGE on 8% or 4%-20% polyacrylamide gradient gels. (7, 10) After transfer to nitrocellulose membranes, blots were blocked for 1 hour in 5% nonfat dried milk dissolved in blotting buffer (50 mM Tris-HCl, 80 mM NaCl, 2 mM CaCl 2 , 0.2% Nonident P40). Membranes were incubated for 1 hour with the primary antibody washed in blotting buffer containing nonfat dry milk and were then incubated with HRP-conjugated second antibody.
Results
CLINICAL PRESENTATION
The index patient (patient 1) was an 11-year boy referred to Makassed Hospital for evaluation of chronic diarrhea since birth. He was born healthy after a full term and uneventful pregnancy and is the first of four children of consanguineous Palestinian parents (Fig. 1A) . Despite the persistence of 8-10 loose greasy stools per day, the patient continued to have normal growth and did not report a history of abdominal pain or distension, vomiting, recurrent infections, or pruritus. However, he experienced prolonged jaundice after birth that lasted for 6 months, with a maximum total bilirubin of 17 mg/dL (direct bilirubin or transaminase activities are not available). At age 10, the patient was evaluated at an outside facility where his routine laboratory tests revealed elevated aminotransferase levels and a borderline elevated international normalized ratio but a normal albumin level (Table 1) . Sweat chloride tests on multiple occasions were also normal. Upon admission, patient 1 had a normal physical examination with normal growth parameters (weight and height were 38 kg and 145 cm, respectively, both of which are at the 50th percentile). The patient's clinical laboratory tests revealed elevated serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT), but negative hepatitis viral serological and autoimmune hepatitis markers, and normal serum levels of immunoglobulins and a1-antitrypsin. Ceruloplasmin levels and a 24-hour urinary copper levels were normal (35 lg/volume, normal 15-50). Plasma levels of cholesterol, triglyceride, albumin, calcium, phosphorous, and coagulation parameters were all within normal ranges. Serum levels of fat-soluble vitamins A, D, and E were markedly diminished. Abdominal CT scan with oral contrast revealed no abnormalities. Upper and lower endoscopies were visually normal with unremarkable duodenal, ileal, and colonic histology. Fecal elastase was normal (400 lg/g [normal, >200 lg/g]) and trial of oral pancreatic enzyme replacement therapy yielded no significant clinical improvement in his diarrhea. Liver ultrasound was reported as normal. Patient 1 underwent a percutaneous liver biopsy at age 10, which showed intact hepatic lobular architecture, mild portal fibrosis without steatosis or inflammation, and no apparent signs of bile retention or bile duct pathology (Fig. 1B,C) . However, the liver copper content was increased to 184 lg/g dry weight (normal, 10-50 lg/g).
The parents reported no gastrointestinal symptoms and their serum liver chemistries, including GGT were normal. However, the family history was significant for a younger sibling, a 3-year-old boy with similar symptoms that began soon after birth. Evaluation of the younger sibling revealed an unremarkable normal physical examination with normal growth parameters. Laboratory studies also revealed elevated serum GGT and aminotransferase levels and markedly reduced serum fat soluble vitamin levels (Table 1) . A colonoscopy revealed visually normal colonic mucosa, but the terminal ileum could not be intubated. Abdominal CT scan with oral contrast showed no abnormalities. Liver ultrasound was also reported as normal. Analysis of plasma and urine for both subjects revealed the normal primary bile acid species, but the levels of bile acids were low in plasma (Table  1) . Daily fat-soluble vitamin supplementation was initiated in both patients (patient 1: 4000 IU vitamin D3, 10,000 IU vitamin A, 200 IU vitamin E; patient 2: 2000 IU vitamin D3, 5000 IU vitamin A, 100 IU vitamin E). Monitoring serum vitamin levels after starting supplementation showed some improvement (Table 1) . Coagulation studies remained borderline elevated without vitamin K supplementation, and both patients had normal ophthalmic examinations without signs of vitamin A deficiency. During the follow-up, both siblings continued to have frequent loose greasy stools, although it was decreasing in frequency with age, consistent with the more severe fat soluble vitamin deficiency in the younger patient. 
EXOME SEQUENCING AND FUNCTIONAL ANALYSIS
The molecular basis for the clinical presentation of diarrhea beginning early in infancy in these brothers was unknown, prompting exome sequencing using DNA from patient 1. The exome analyses yielded 39.4 million confidently mapped reads with a mean coverage of X59. Following alignment and variant detection, variants were removed if called less than X8, were offtarget, heterozygous, synonymous, affected nonconserved residues, or had a MAF>0.1% at dbSNP138 or MAF>1% in the Hadassah-Hebrew University Medical Center's SNP dataset. The Hadassah-Hebrew University Medical Center's SNP dataset was generated inhouse and is more reflective of the population it serves than dbSNP. Fifteen homozygous variants remained after this filtering (Supporting Table S1 ), none of which had previously been associated with diarrhea of infancy. Attention was then focused on chr15:65342421 delT, NM_178859:c.79delT:p.F27fs in SLC51B because of its putative relevance to the proband's symptoms. Sanger sequencing disclosed complete segregation of the variant with the disease in the family (Fig. 1) . The variant is not carried by any of the approximately 60,000 individuals whose exome analyses were deposited at Exome Aggregation Consortium. (12) The chr15:65342421 delT is located in the first coding exon of SLC51B and induces a frameshift at codon position 27 and premature stop at codon 50 ( Fig. 2A) . The premature termination codon in the mutant SLC51B gene lies 37 nucleotides from the 3 0 -most exon-exon junction, suggesting that the predicted transcript arising from this gene is not a candidate for nonsense-mediated decay. (13) The mutant transcript encodes a predicted 49-amino acid polypeptide with a unique 21-amino acid C-terminus. Although the N-terminal domain is intact, the frameshift results in truncation of the predicted transmembrane domain and loss of sequences previously shown to be important for the topologically correct insertion of OSTb protein in the membrane, for interaction with its partner protein OSTa, and for solute transport function (Fig. 2) . (14, 15) Exome sequencing revealed no additional coding variants in SLC51B (OSTb) or SLC51A (OSTa) (Supporting Table S2 ).
The effects of the OSTb p.F27fs mutation on protein expression and transport activity were investigated in transfected COS cells. OSTa-OSTb exhibits bidirectional transport when expressed in transfected cells or Xenopus oocytes, and studies suggest that it operates by facilitated diffusion, mediating solute uptake or efflux depending on the electrochemical gradient. (6, 7) To examine the functional consequences of the OSTb p.F27fs mutation, taurocholate uptake was examined in COS cells transfected with OSTa and either the wild-type or mutant OSTb. Wild-type OSTa-OSTb exhibited robust uptake of radiolabeled taurocholate with an apparent Michaelis constant (K m ) of approximately 698 lM, similar to that previously reported for taurocholate uptake by skate Osta-Ostb (K m 5 785 lM). (16) . In contrast, taurocholate transport activity in COS cells transfected with wild-type OSTa plus mutant OSTb was reduced more than 98% to levels observed in COS cells transfected with wild type OSTa plus yellow fluorescent protein expression plasmid (Fig. 3A) . As shown in Fig. 3B , monomeric and multimeric forms of OSTa protein were readily detected when coexpressed with wild-type OSTb but was almost undetectable when coexpressed with mutant OSTb or in the absence of OSTb. Wild-type OSTb protein was readily detected when coexpressed with OSTa, but no mutant OSTb protein was detected using an antibody directed against the N terminus of the protein.
Discussion
The heteromeric transporter OSTa-OSTa was originally discovered by Ballatori and coworkers and its role as the major basolateral membrane transporter responsible for ileal enterocyte bile acid export was clearly established in mouse models. (7) (8) (9) 16) However, the contribution of OSTa-OSTb to the enterohepatic circulation of bile acids and disease in humans remains to be defined. In the present study, we identified and characterized a phenotypic loss-offunction SLC51B mutation in a family with two siblings who presented with intractable diarrhea of infancy, elevated serum liver enzymes, and features of cholestasis.
SLC10A2 (ASBT) mutations in humans yields a primary bile acid malabsorption phenotype, with increased fecal loss of bile acids, steatorrhea, and fatsoluble vitamin deficiency in the absence of ileal histological or ultrastructural changes. (2, 17, 18) The patients in this report presented with similar chronic diarrhea beginning soon after birth. However, there also appear to be important phenotypic differences, particularly elevated liver enzymes (more so for GGT than ALT or AST), elevated liver copper, and liver histological changes, which had not been noted in previously described cases of infantile diarrhea associated with primary bile acid malabsorption. (19) In humans, expression of OSTa-OSTb has been localized to hepatocytes and cholangiocytes in addition to ileal enterocytes. (6) As such, loss of OSTa-OSTb function in liver and abnormal retention of bile acids in hepatocytes or cholangiocytes may underlie the increases in liver chemistries, with the greater elevation of GGT activity suggestive of a cholangiolar pathology.
Due to the limited availability of serial clinical examinations and biospecimens, several key features of these two brothers' clinical courses remain unknown. As such, the potential for pathological progression or adaptation in response to loss of OSTa-OSTb function is unclear. Key issues that may help clinicians identify other patients with OSTb deficiency may include chronic diarrhea with normal growth, low serum bile acid levels, severe fat soluble vitamin deficiencies, and liver enzyme elevations, particularly GGT.
In conclusion, through exome sequencing and cell culture validations, we have identified an inherited defect in the heteromeric bile acid and organic solute transporter OSTa-OSTb as a cause of congenital diarrhea and mild cholestasis. The identification and characterization of these OSTb-deficient patients suggests that OSTa-OSTb plays a major role in bile acid homeostasis and gut-liver function, as predicted by studies using knockout mouse models. (8) (9) (10) In addition, defects in the genes encoding either OSTa or OSTb may represent an inherited form of infantile cholestasis.
